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Trade and Health: 
Is the Health Community Ready for Action?
Kelley Lee*, Meri Koivusalo
Trade is the lifeblood of all commerce. The exchange of goods and services has played 
a deﬁ ning role in human history, 
creating vast empires, encouraging 
mass migration, and sometimes 
tipping the balance between peace 
and conﬂ ict. It is thus unsurprising 
that protecting and encouraging 
international trade has remained a top 
priority for governments, businesses 
and international organisations. 
Historically, the protection of 
health has been a permitted reason 
for restricting trade. Trade brought 
plague to Athens in 430 BC, killing as 
much as one third of the population, 
as well as to fourteenth century Europe 
after which quarantine practices were 
introduced. During the nineteenth 
century, ﬂ ourishing trade also 
facilitated the spread of diseases such 
as cholera. This prompted a series of 
International Sanitary Conferences 
among leading trading nations, and 
the adoption of International Sanitary 
Conventions (forerunners of the 
present day International Health 
Regulations). While protecting health 
was a clear aim, in reality the primary 
task was to minimise interference by 
health matters on trade.
Today, there are greater tensions 
than ever before between promoting 
trade and protecting health because 
of globalisation. Successive rounds 
of trade negotiations held since the 
Second World War, under the General 
Agreement on Trade and Tariffs 
and, since 1995, the World Trade 
Organization (WTO), have substantially 
reduced tariff levels and standardised 
trading practices across countries. 
This process of trade liberalisation has 
signiﬁ cantly increased trade volumes, 
bringing more and more countries 
into the world trading system. For 
the public health community, trade 
has raced ahead of corresponding 
measures to protect health. Efforts to 
ensure that there is an appropriate 
balance between the two policy areas 
has become a difﬁ cult challenge.
Tensions between Trade 
and Health
The right to restrict trade to protect 
the health of humans, animals, and 
plants is recognised by the General 
Agreement on Trade and Tariffs 
(Article XX) under two conditions: 
(1) the restriction is applied in a 
nondiscriminatory way; and (2) the 
restriction is based on recognised 
scientiﬁ c evidence. Countries are 
allowed to restrict trade, for example, 
of certain goods such as radioactive 
waste or infected food products. 
Disputes can arise if the restriction is 
believed to be discriminatory or there 
is disagreement about the scientiﬁ c 
evidence supporting it (see sidebar). 
The ban introduced by the European 
Community in 1989 on hormone-
treated beef imported from the US. 
led to two rulings by the Dispute 
Settlement Body of the WTO in favour 
of the American government. The 
assessment of the evidence primarily 
by trade experts, rather than public 
health experts, is a clear problem of 
the existing dispute settlement process. 
The process also makes it difﬁ cult to 
regulate inappropriate production 
methods which do not lead to problems 
in the end product but may be of 
public health concern. For example, 
the practice of using hormones to 
boost meat production may prove 
problematic in future research, even 
if residues in the meat are not judged 
high enough at present to warrant 
sufﬁ cient proof of health concerns. 
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Recent Disputes between Trade 
and Health
Growth-Promoting Hormones
In 1998 WTO ruled that a European 
Community ban of the use of certain 
growth-promoting hormones was not 
based on an appropriate risk assessment. 
Rather than lift the ban, the EU sought 
new evidence of the risk to human health 
of hormone residues in meat products. 
In 1999 Canada and the US imposed 
trade sanctions worth US$116.8 million 
and Cdn$11.3 million. In 2003 the EU 
announced that, based on new scientifi c 
evidence, the ban will remain in place and 
asked the US and Canada to lift sanctions.
Chrysotile Asbestos
In 2001 WTO ruled that the European 
Community was permitted to ban the 
import of chrysotile asbestos on the 
grounds of protecting public health, and 
rejected the Canadian government’s 
claim that the ban was discriminatory 
and an unnecessary barrier to trade. 
While the decision shows that WTO 
panel decisions can prioritise health, 
the process and grounds of the 
decision indicates that, even with such 
a well-established carcinogen, the 
dispute settlement process required 
extensive argument by the public health 
community.
The Essay section contains opinion pieces on topics 
of broad interest to a general medical audience. 
PLoS Medicine  |  www.plosmedicine.org 0013
Moreover, tight regulations on trade 
that are intended to protect health can 
come under ﬁ re from the trade lobby. 
Two World Bank studies argue, for 
instance, that European Union (EU) 
regulations on pesticides in bananas, as 
well as aﬂ atoxins, could be interpreted 
as barriers to trade and market access 
[1,2]. 
The short shrift given to 
precautionary measures to protect 
health, where existing scientiﬁ c 
evidence is deemed insufﬁ cient, 
reﬂ ects a further inbuilt priority given 
to trade. Growing concerns over the 
development and use of genetically 
modiﬁ ed organisms (GMOs), for 
example, have been dismissed by 
major companies such as Monsanto 
and Cargill on the basis of a lack of 
existing scientiﬁ c evidence of harm to 
health. Consumer groups and public 
health advocates, however, argue 
that the subject is still in its scientiﬁ c 
infancy. Where new causal pathways 
or systemic impacts of environmental 
exposures are of concern, such as with 
GMOs, at best one can say that the jury 
is still “out”. Hence, allowing GMOs to 
be spread widely, rather than taking 
precautionary measures, could prove to 
have irreversible consequences.
The classiﬁ cation of certain goods 
as a risk to health, and thus subject to 
trade restrictions, is also a source of 
dispute. The best example is tobacco 
products which manufacturers argue 
should be treated like other traded 
goods. Public health advocates, 
however, argue that because tobacco is 
harmful to health, it should be subject 
to special restrictions. A battle over 
tobacco is currently being played out 
in regional trade negotiations and will 
be raised at forthcoming multilateral 
negotiations over agricultural trade. 
Whether the public health community 
will be able to argue successfully to 
protect health, when pitted against the 
vast resources of a multi-billion dollar 
industry, remains to be seen.
The TRIPs Agreement
Two new sources of tension have arisen 
in recent years—intellectual property 
rights (IPRs) and trade in services. 
The protection of IPRs is a new feature 
of international trade law, coming 
into force under the Agreement on 
Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) adopted 
in 1994. The agreement sets out 
minimum standards for 
protecting and enforcing 
patents, trademarks, and 
copyrights. 
Since the mid-1990s 
there has been increasing 
concern over access to 
drugs in the developing 
world, and especially 
drugs for treating HIV/
AIDS. This issue gained 
international attention 
when the South African 
government sought to 
access cheaper versions 
of patent protected 
drugs, but was faced with 
strong opposition by the 
pharmaceutical industry. 
The importance of 
public health priorities, 
and the existence 
of ﬂ exibility within 
TRIPS, was eventually 
conﬁ rmed in the Doha 
Declaration on the 
TRIPS Agreement and 
Public Health signed in 
2001 [3]. The agreement allows for 
“compulsory licensing”, which means 
that local manufacturers in poor 
countries are allowed to make cheap 
versions of patented drugs during 
public health emergencies, provided 
that they give a royalty payment to 
the patent holder. Nonetheless, IPRs 
protection has remained a problem 
given continued disagreement by the 
US over which diseases and countries 
are covered under the declaration. The 
capacity to protect IPRs has also been 
enhanced by the shift towards bilateral 
trade negotiations as a result of the 
breakdown in multilateral negotiations 
under the WTO.
While international debates over 
TRIPS have so far focused on the 
developing world, it is clear that there 
are issues relevant to the public health 
community as a whole concerning 
open access to a wide range of health-
related knowledge and information. 
The possible beneﬁ ts and costs of 
the TRIPS agreement had not been 
openly discussed beforehand. Rather, 
its measures were heavily inﬂ uenced by 
industries seeking to exert ownership 
over intellectual goods such as 
research, information, and other 
data sources. Within an increasingly 
competitive world market, companies 
are driven to recoup their investment 
in such resources through IPRs. For 
the public health community, however, 
there is a vital need for affordable and 
open access by all to such resources. 
Leaving the commercial market to 
drive research and development (R&D) 
can lead not only to problems of access 
in developing countries but it can also 
lead to the neglect of research and 
public health priorities in all countries, 
such as research on antibiotics, which 
has been deemed insufﬁ ciently 
proﬁ table [4]. Concern over the 
impact of intellectual property rights 
and marketing monopolies on overall 
pharmaceutical policies, pricing and 
R&D of pharmaceuticals has also led 
to proposals for a new trade framework 
for global health care R&D efforts [5]. 
Trade in Health Services
The General Agreement on Trade 
in Services (GATS) is another 
expanded area of trade law. Services 
are the fastest-growing segment of 
the world economy, providing more 
than sixty percent of global output 
and employment. In the past, most 
services were not considered to be 
tradable across borders. Advances in 
communications technology, including 
the rise of e-commerce, and regulatory 
changes have made it easier to deliver 
services across borders. For trade in 
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There is a fi ne balance between protecting patents and 
ensuring access to essential drugs in the developing world 
(Illustration: Margaret Shear)
PLoS Medicine  |  www.plosmedicine.org 0014
health services, the implications are not 
yet clear. 
It is generally expected that GATS 
would not apply to public services due 
to a general exemption on the matter. 
However, this exclusion is very narrowly 
worded, and based on a model of 
public services which may no longer 
hold. Health sector reforms have 
changed the ways in which publicly 
ﬁ nanced services are provided in many 
countries, including the extensive 
use of contracting out and managed 
competition. In most countries, 
this includes both medical care and 
related services such as laboratory or 
ambulance services. Health services, 
which are contracted out to the non-
proﬁ t or for-proﬁ t sector, are likely 
to be no longer considered purely 
“public” and thus protected by the 
exclusion. Recent legal reviews of the 
GATS [6,7] conﬁ rm this concern, 
describing how the agreement would 
apply to any health-related service 
supplied on a “commercial” basis. 
Whether paid for directly by the patient 
or through a social security fund, the 
expectation that GATS negotiations 
will not apply to public services may no 
longer hold.
Given this, the two reviews warn that 
there are valid grounds to suggest that 
negotiations on trade in services, and 
full commitments in health services in 
GATS, will have important implications 
for the ways in which national health 
systems and policies are implemented. 
While GATS may not directly limit 
the aims of national health policies, 
commitments under GATS can 
inﬂ uence the ability of governments 
to implement health policies and 
regulate commercial service providers. 
This could apply especially to efforts to 
introduce new regulations that restrict 
market forces. The current GATS 
negotiations on domestic regulation 
include requirements of least trade 
restrictiveness and necessity tests for 
introducing regulatory measures in 
committed sectors. These requirements 
could pose difﬁ culties if a government 
sought, for example, to oblige hospitals 
to operate on a non-proﬁ t basis. This 
might be interpreted under the GATS 
as restricting market forces. In this 
way, GATS could effectively inﬂ uence 
the scope of national health policy, 
even challenging the capacity of 
governments to pursue health policies 
that prioritise universal access, cost 
containment, and quality control.
Challenges to the Health 
Community
As world trade continues to expand in 
scale and scope, the health community 
faces a number of key challenges. 
We must be armed with a better 
understanding of the world trading 
system, notably the legal framework for 
international trade. Comprehending 
the potential health implications 
of various bilateral, regional, and 
multilateral agreements regulating 
trade today is a daunting task. 
Although the public health community 
has fewer resources at its disposal than 
the proponents of trade liberalisation, 
it is clear that health priorities do have 
strong support by citizens all over the 
world. 
It is critically important for the 
health community to challenge the 
value-based assumption that trade 
liberalisation, rather than human 
welfare, should be given automatic 
priority. Indeed, ignoring health can 
lead to problems in the trade sphere. 
The outbreaks of bovine spongiform 
encephalopathy in Europe and North 
America and severe acute respiratory 
syndrome in Asia emphasised that trade 
can be severely disrupted by insufﬁ cient 
measures to protect health. The health 
community has to press for a much 
louder voice in the setting of trade 
policy at the national and international 
levels. A balance between trade and 
health policies can only be achieved if 
the health community is prepared to 
be far more vocal, and the trade policy 
community is prepared to listen. 
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Trade can be severely 
interrupted by 
insuffi cient measures 
to protect health.
